- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02398058
Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS) (TOMAS)
April 13, 2021 updated by: Italian Sarcoma Group
A Phase Ib Study on the Combination of Trabectedin and Olaparib in Unresectable Advanced/Metastatic Sarcomas After Failure of Standard Therapies
This is a Phase 1b, multi-site, open-label, non-randomized clinical trial evaluating the safety, tolerability, and pharmacokinetics of escalating doses of olaparib and trabectedin in patients with unresectable advanced/metastatic sarcomas.
Patients will continue to be treated on this combination regimen in the absence of disease progression, intolerable toxicity or patient's decision.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bologna, Italy, 40136
- Istituti Ortopedici Rizzoli - Unit of chemotherapy of Muscoloskeletal Tumors
-
Milano, Italy, 20133
- Istituto Nazionale Tumori - Unit of Medical Oncology
-
-
Torino
-
Candiolo, Torino, Italy, 10060
- Fondazione Del Piemonte Per L'Oncologia Ircc Candiolo
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- written informed consent
- histologically documented and not surgically resectable or metastatic sarcomas which progressed after first or further line treatments for relapsing disease
- Measurable disease as defined by RECIST v1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0/1. ECOG PS 2 are eligible if depends solely on orthopedic problems
- Estimated life expectancy of ≥ 4 months
- Age ≥18 years
- Adequate organ function: Hemoglobin > 10.0 g/dl; Absolute neutrophil count (ANC) >1,500/mm3; Platelet count >= 100,000/μl; Total bilirubin < 1.5 times the upper limit of normal (ULN); ALT and AST < 2.5 x ULN (< 5 x ULN for patients with liver involvement of their cancer); Alkaline phosphatase < 2.5 x ULN; PT-INR/PTT < 1.5 x ULN; Serum creatinine < 1.5 x ULN or creatinine clearance ≥ 50 ml/min; Albumin > 25 g/l; Creatine phosphokinase (CPK) < 2.5 x ULN
Exclusion Criteria:
- Involvement in the planning and/or conduct of the study
- Previous enrolment in the present study
- Participation in another clinical study with an investigational product during the last month
- Persistent toxicities (≥CTCAE grade 2) with the exception of alopecia, caused by previous anticancer therapies
- Dementia or significantly altered mental status
- Patients with any severe and/or uncontrolled medical conditions
- HIV infection
- Active clinically serious infections (> grade 2 NCI-CTCAE version 4.03).
- Active viral hepatitis (HBV or HCV infection)
- Symptomatic metastatic brain or meningeal tumors (unless the patient is > 6 months from definitive therapy, does not require corticosteroid treatment, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry).
- Patients with seizure disorders requiring medication (such as steroids or anti-epileptics)
- Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days before the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and 5 months after last dose of study drug
- Patients with evidence or history of bleeding diathesis
- Patients undergoing renal dialysis
- Patients unable to swallow oral medications
- Uncontrolled diabetes (fasting glucose > 2 x ULN)
- Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent (except corticosteroids with a daily dosage equivalent to prednisone ≤ 20 mg for adrenal insufficiency). Topical or inhaled corticosteroids are permitted
- Patients with a history of another malignancy within 5 years prior to study entry, except curatively treated non-melanotic skin cancer or in-situ cervical cancer or other solid tumors curatively treated with no evidence of disease for ≥5 years.
- Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of treatment start
- Radiotherapy during study or within 3 weeks of start of study drug. (Palliative radiotherapy allowed)
- Major surgery within 4 weeks of start of study
- Prior exposure to the study drugs or their analogues
- Patients with known hypersensitivity to trabectedin, olaparib or to their excipients
- Patients can receive a stable dose of bisphosphonates for bone metastases before and during the study as long as these were started at least 4 weeks prior to treatment with the study drugs
- Substance abuse, medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
- A history of noncompliance to medical regimens or inability or unwillingness to return for scheduled visits
- Corrected QT interval on the 12-lead ECG (QTc) >470 msec (Bazett Formula)
- use of strong CYP3A4 inhibitors/inducers
- Patients with myelodysplastic syndrome/acute myeloid leukemia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Trabectedin plus olaparib
All patients will be treated with trabectedin and olaparib in an open-label fashion. The dosage of the drugs at which each patient is treated depends on the dose level reached at the time of enrollment. |
trabectedin will be administered in a 24-h continuous i.v.
infusion every 3 weeks
Other Names:
olaparib will be administered in a continuous daily dose every 12 hours
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
maximum tolerated dose
Time Frame: from start up to 6 weeks
|
safety will be evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) v 4.03
|
from start up to 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best Overall Response
Time Frame: baseline and every 2 cycles (6 weeks +/- 1 week) up to 2 years
|
best overall response will be defined according to the Response Evaluation Criteria in Solid Tumor version 1.1 (RECIST v 1.1)
|
baseline and every 2 cycles (6 weeks +/- 1 week) up to 2 years
|
Clinical Benefit Rate
Time Frame: baseline and every 2 cycles (6 weeks +/- 1 week) up to 2 years
|
Clinical Benefit Rate (CBR): will be defined as the rate of CR (complete response) + PR (partial response) + stable disease lasting at least 12 weeks.
CR, PR and stable disease will be defined according to RECIST v 1.1.
|
baseline and every 2 cycles (6 weeks +/- 1 week) up to 2 years
|
Growth Modulation Index
Time Frame: baseline and every 2 cycles (6 weeks +/- 1 week) up to 2 years
|
Growth modulation index (GMI) will be calculated as: GMI=TTPn/TTPn-1.
TTPn: Time To Progression on the new agent.
TTP n-1: Time To Progression on the treatment the patient received just before the new agent was started.
|
baseline and every 2 cycles (6 weeks +/- 1 week) up to 2 years
|
Overall Survival
Time Frame: baseline and up to 2 years
|
time from the date of enrollment to date of death or to the date being censored at two years (whichever occurs first).
|
baseline and up to 2 years
|
Duration of Tumor Response
Time Frame: baseline and every 2 cycles (6 weeks +/- 1 week) up to 2 years
|
Duration of Objective Response (complete or partial responses) will be measured from the date that a complete or partial response is first documented (whichever occurs first) to date of progression or death due to progressive disease, whichever occurs first.
|
baseline and every 2 cycles (6 weeks +/- 1 week) up to 2 years
|
Progression-Free Survival (PFS)
Time Frame: baseline and every 2 cycles (6 weeks +/- 1 week) up to 2 years
|
PFS is defined as the time from the date of enrollment to the date of first documentation of disease progression, or to the death from any cause.
|
baseline and every 2 cycles (6 weeks +/- 1 week) up to 2 years
|
Pharmacokinetic of trabectedin (AUC)
Time Frame: baseline, days 1-2-3-4-5-8-15 of the first two cycles
|
The concentration-time data will be used for a preliminary assessment of the effect of combination therapy on the single-dose pharmacokinetics of trabectedin and olaparib.
The data will be analyzed by noncompartmental methods.
Pharmacokinetic parameters for trabectedin: steady state profile, end of infusion concentration, area under the concentration-time curve (AUC), and, if data permit, terminal phase half-life.
For these parameters, the following descriptive statistics will be calculated: mean, standard deviation, coefficient of variation, median, and geometric mean.
Any drug-drug interaction will be thoroughly searched.
For both trabectedin and olaparib all pharmacokinetic evaluations will be done only for the first 2 cycles.
|
baseline, days 1-2-3-4-5-8-15 of the first two cycles
|
Pharmacokinetic of olaparib (steady state profile and so maximum concentration, minimal concentration, and AUC will be calculated)
Time Frame: baseline, day -5 cycle 1, day 1 cycle 2, of the first two cycles
|
The concentration-time data will be used for a preliminary assessment of the effect of combination therapy on the single-dose pharmacokinetics of trabectedin and olaparib.
The data will be analyzed by noncompartmental methods.
The following pharmacokinetic parameter values will be obtained for olaparib: steady state profile and so maximum concentration, minimal concentration, and AUC will be calculated.
For these parameters, the following descriptive statistics will be calculated: mean, standard deviation, coefficient of variation, median, and geometric mean.
Any drug-drug interaction will be thoroughly searched.
For both trabectedin and olaparib all pharmacokinetic evaluations will be done only for the first 2 cycles.
|
baseline, day -5 cycle 1, day 1 cycle 2, of the first two cycles
|
safety evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) v 4.03
Time Frame: baseline up to 28 days after last dose of study treatment up to 2 years
|
safety will be evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) v 4.03
|
baseline up to 28 days after last dose of study treatment up to 2 years
|
Biomarkers (composite outcome)
Time Frame: baseline, day 1-2-8-15 of each cycle up to 2 years
|
Several gene assessments (expression, amplification/ deletion, single nucleotide polymorphisms) on DNA-damage response-related markers (including but not limited to BRCA 1-2, ERCC 1-2-5, XRCC 1-2-3, RAD51 and 53BP1, PARP 1-2, P-histone H2AX and others) will be conducted.
Statistical analysis will be performed to investigate the association between trial outcomes and polymorphisms of these genes.
|
baseline, day 1-2-8-15 of each cycle up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Giovanni Grignani, MD, Italian Sarcoma Group
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Vyse S, Thway K, Huang PH, Jones RL. Next-generation sequencing for the management of sarcomas with no known driver mutations. Curr Opin Oncol. 2021 Jul 1;33(4):315-322. doi: 10.1097/CCO.0000000000000741. Review.
- Grignani G, D'Ambrosio L, Pignochino Y, Palmerini E, Zucchetti M, Boccone P, Aliberti S, Stacchiotti S, Bertulli R, Piana R, Miano S, Tolomeo F, Chiabotto G, Sangiolo D, Pisacane A, Dei Tos AP, Novara L, Bartolini A, Marchesi E, D'Incalci M, Bardelli A, Picci P, Ferrari S, Aglietta M. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. Lancet Oncol. 2018 Oct;19(10):1360-1371. doi: 10.1016/S1470-2045(18)30438-8. Epub 2018 Sep 11.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 20, 2014
Primary Completion (Actual)
December 1, 2019
Study Completion (Actual)
December 1, 2019
Study Registration Dates
First Submitted
January 14, 2015
First Submitted That Met QC Criteria
March 24, 2015
First Posted (Estimate)
March 25, 2015
Study Record Updates
Last Update Posted (Actual)
April 14, 2021
Last Update Submitted That Met QC Criteria
April 13, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Musculoskeletal Diseases
- Bone Diseases
- Sarcoma
- Bone Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Poly(ADP-ribose) Polymerase Inhibitors
- Olaparib
- Trabectedin
Other Study ID Numbers
- TOMAS
- 2013-003638-33 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Soft Tissue Sarcoma
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue Sarcoma | Stage IIA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma
-
CytRxUnknownUnresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States, Australia, Russian Federation, Hungary, India, Romania, Ukraine
-
University of WashingtonAadi Bioscience, Inc.Active, not recruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue SarcomaUnited States
-
National Institutes of Health Clinical Center (CC)CompletedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IVA Adult Soft Tissue Sarcoma | Stage IIB Adult Soft Tissue Sarcoma | Stage IIC Adult Soft Tissue Sarcoma | Stage IVB Adult Soft Tissue Sarcoma
-
National Cancer Institute (NCI)TerminatedRecurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Stage I Adult Soft Tissue Sarcoma | Stage II Adult Soft Tissue SarcomaUnited States
-
National Cancer Institute (NCI)RecruitingMetastatic Alveolar Soft Part Sarcoma | Unresectable Alveolar Soft Part Sarcoma | Advanced Soft Tissue Sarcoma | Advanced Alveolar Soft Part SarcomaUnited States
-
Centre Leon BerardNovartis; National Cancer Institute, FranceRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
UNICANCERRecruitingAdvanced Soft-tissue Sarcoma | Metastatic Soft-tissue SarcomaFrance
-
University of Colorado, DenverAgenus Inc.RecruitingAdvanced Soft Tissue Sarcoma | Metastatic Soft Tissue SarcomaUnited States
-
Wake Forest University Health SciencesMerck Sharp & Dohme LLCCompletedSoft Tissue Sarcoma, Adult | Soft Tissue Sarcoma, ChildUnited States
Clinical Trials on trabectedin
-
Italian Sarcoma GroupAstraZeneca; PharmaMarActive, not recruitingAdvanced Soft Tissue SarcomaItaly
-
Italian Sarcoma GroupPharmaMarWithdrawnLeiomyosarcoma | Liposarcoma | Synovial SarcomaItaly
-
PharmaMar, SpainCompletedSoft Tissue SarcomaGermany
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Completed
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedSarcomaUnited States
-
European Organisation for Research and Treatment...CompletedSarcoma | Small Intestine Cancer | Ovarian Cancer | Brain and Central Nervous System Tumors | Endometrial Cancer | Gastrointestinal Stromal Tumor
-
European Organisation for Research and Treatment...CompletedUnspecified Adult Solid Tumor, Protocol SpecificFrance, Spain, Denmark, Netherlands, Norway, Belgium, United Kingdom, Israel, Italy, Switzerland, Germany, Austria, Greece, Portugal
-
University of Colorado, DenverWithdrawn
-
Grupo Español de Investigación en Cáncer de OvarioCompleted
-
PharmaMarCompletedRelapsed Ovarian CancerSpain, France, Italy, Belgium, Germany